Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 10/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.37 |
| ▸ | COMT | P21964 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647910 | 0.91 | PTPN1 (0.58) | PTPN1COMTPTPN2NOX4ALDH1A1 | |
| SCHEMBL2933785 | 0.86 | PTPN1 (0.42) | PTPN1ALDH1A1 | |
| SCHEMBL4316679 | 0.84 | PTPN1 (0.57) | PTPN1NR1H3PTPN2NR1H2 | |
| SCHEMBL3221771 | 0.84 | PTPN1 (0.52) | PTPN1NR1H3PTPN2NR1H2 | |
| SCHEMBL629646 | 0.84 | PTPN1 (0.52) | PTPN1COMTPTPN2NOX4ALDH1A1 | |
| SCHEMBL3213043 | 0.84 | PTPN1 (0.49) | PTPN1COMTPTPN2 | |
| SCHEMBL3215930 | 0.84 | PTPN1 (0.56) | PTPN1NR1H3PTPN2NR1H2 | |
| SCHEMBL3213356 | 0.83 | PTPN1 (0.58) | PTPN1NR1H3PTPN2 | |
| SCHEMBL3214264 | 0.82 | PTPN1 (0.53) | PTPN1NR1H3PTPN2NR1H2 | |
| SCHEMBL2933467 | 0.80 | PTPN1 (0.58) | PTPN1NR1H3PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | claimed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | claimed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (SZ) | 2010-12-02 | — | — | US | disclosed |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | JEYASEELAN JEY RAJU | 2010-02-11 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | PTPN1 21/4885NR1H3 1071/4885COMT 744/4885 |
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | MUSK, PPP5C, PPP3CA | PTPN1 35/4885NR1H3 4594/4885COMT 2858/4885 |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | PPM1A, TNNI3, PTPA | PTPN1 41/4885NR1H3 3959/4885COMT 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.